<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">Colorectal cancers</z:e> develop via two major pathways that include <z:mp ids='MP_0008866'>chromosomal instability</z:mp> and microsatellite instability </plain></SENT>
<SENT sid="1" pm="."><plain>Microsatellite instability occurs due to deficient DNA mismatch repair (MMR), which can be caused by epigenetic silencing of the MLH1 MMR gene in <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> or germline mutations in MMR genes that result in <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>While the molecular origin of deficient MMR differs, <z:hpo ids='HP_0003745'>sporadic</z:hpo> and <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> share similar pathological features and have a more favorable stage-adjusted prognosis compared with MMR-proficient cases </plain></SENT>
<SENT sid="3" pm="."><plain>While controversy remains, there is evidence to suggest that deficient MMR may predict a lack of benefit from <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>-based adjuvant chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>The focus of this article is on the MMR phenotype and its prognostic and predictive implications for the management of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>